scholarly journals Liquid Biopsy: Circulating Tumor Cells and its Impact on Follow-up/Treatment of Prostate Cancer Patients

2014 ◽  
Vol 13 (4) ◽  
pp. 196-200
Author(s):  
İbrahim Kulaç
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Liquid Biopsy

Clinical validation of a medical device for in vivo isolation of circulating tumor cells in prostate cancer patients: One-year follow-up.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. e16027-e16027 ◽  
Author(s):  
Gerit Theil ◽  
Kersten Fischer ◽  
Thomas Krahn ◽  
Andre Schumann ◽  
Kathrin Haubold ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Tumor Cells ◽  
Medical Device ◽  
Circulating Tumor Cells ◽  
Clinical Validation ◽  
One Year

scholarly journals Circulating Tumor Cells as a Marker of Disseminated Disease in Patients with Newly Diagnosed High-Risk Prostate Cancer

Cancers ◽  
2020 ◽  
Vol 12 (1) ◽  
pp. 160 ◽  
Author(s):  
Wojciech A. Cieślikowski ◽  
Joanna Budna-Tukan ◽  
Monika Świerczewska ◽  
Agnieszka Ida ◽  
Michał Hrab ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
High Risk ◽  
Cancer Patients ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Metastatic Disease ◽  
Newly Diagnosed ◽  
High Risk Prostate Cancer ◽  
Intergroup Comparison ◽  
Risk Prostate Cancer

The aim of this study was to investigate whether the enumeration of circulating tumor cells (CTCs) in blood can differentiate between true localized and metastatic prostate cancer. A cross-sectional study of 104 prostate cancer patients with newly diagnosed high-risk prostate cancer was conducted. In total, 19 patients presented metastatic disease and 85 were diagnosed with localized disease. Analyses included intergroup comparison of CTC counts, determined using the CellSearch® system, EPISPOT assay and GILUPI CellCollector®, and ROC analysis verifying the accuracy of CTC count as a maker of disseminated prostate cancer. The vast majority (94.7%) of patients with advanced-stage cancer tested positively for CTCs in at least one of the assays. However, significantly higher CTC counts were determined with the CellSearch® system compared to EPISPOT assay and GILUPI CellCollector®. Identification of ≥4 CTCs with the CellSearch® system was the most accurate predictor of metastatic disease (sensitivity 0.500; specificity 0.900; AUC (95% CI) 0.760 (0.613–0.908). Furthermore, we tried to create a model to enhance the specificity and sensitivity of metastatic prediction with CTC counts by incorporating patient’s clinical data, including PSA serum levels, Gleason score and clinical stage. The composite biomarker panel achieved the following performance: sensitivity, 0.611; specificity, 0.971; AUC (95% CI), 0.901 (0.810–0.993). Thus, although the sensitivity of CTC detection needs to be further increased, our findings suggest that high CTC counts might contribute to the identification of high-risk prostate cancer patients with occult metastases at the time of diagnosis.

Sign in / Sign up

Export Citation Format

Share Document